Ratio Revelations: Karyopharm Therapeutics Inc (KPTI)’s Financial Metrics in the Spotlight

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed the day trading at $0.97 up 2.20% from the previous closing price of $0.95. In other words, the price has increased by $2.20 from its previous closing price. On the day, 1.24 million shares were traded. KPTI stock price reached its highest trading level at $1.02 during the session, while it also had its lowest trading level at $0.9308.


For a better understanding of KPTI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.99 and its Current Ratio is at 3.04.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.

On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.

JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 06 ’24 when Paulson Richard A. sold 3,576 shares for $1.13 per share. The transaction valued at 4,041 led to the insider holds 1,153,697 shares of the business.

Rangwala Reshma sold 6,789 shares of KPTI for $7,943 on Apr 22 ’24. The EVP & Chief Medical Officer now owns 342,931 shares after completing the transaction at $1.17 per share. On Apr 04 ’24, another insider, Paulson Richard A., who serves as the President and CEO of the company, sold 3,563 shares for $1.29 each. As a result, the insider received 4,596 and left with 1,157,273 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 114072760 and an Enterprise Value of 274410016. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.81. Its current Enterprise Value per Revenue stands at 1.954 whereas that against EBITDA is -2.078.

Stock Price History:

Over the past 52 weeks, KPTI has reached a high of $2.47, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -19.04%, while the 200-Day Moving Average is calculated to be -12.76%.

Shares Statistics:

Over the past 3-months, KPTI traded about 1.24M shares per day on average, while over the past 10 days, KPTI traded about 1254310 shares per day. A total of 114.92M shares are outstanding, with a floating share count of 102.40M. Insiders hold about 13.00% of the company’s shares, while institutions hold 63.83% stake in the company. Shares short for KPTI as of 1715731200 were 17559879 with a Short Ratio of 14.14, compared to 1713139200 on 23560996. Therefore, it implies a Short% of Shares Outstanding of 17559879 and a Short% of Float of 15.229999999999999.

Most Popular